これは2023-05-19 10:41:39 UTCで公開された古いバージョンです。最新バージョンをお読みください。
プレプリント / バージョン1

Effectiveness of mask in COVID-19 pandemic in Japan

##article.authors##

  • Kurita, Junko Department of Nursing, Faculty of Sport and Health Science, Daito Bunka University
  • Tamie Sugawara Infectious Disease Surveillance Center, National Institute of Infectious Diseases
  • Yasushi Ohkusa Infectious Disease Surveillance Center, National Institute of Infectious Diseases

DOI:

https://doi.org/10.51094/jxiv.381

キーワード:

SARS-CoV-2、 effective reproduction number、 mask、 vaccine coverage、 waning in vaccine effectiveness

抄録

Background: The government of Japan had stopped to recommend to wear mask on March 13, 2023.

Object: The object of this study was to estimate effectiveness of mask to prevent for COVID-19 infection through comparison among before and after the stopping date.

Method: The effective reproduction number(R(t)) was regressed on dummy variable for after the stopped date as well as vaccine coverage, vaccine coverage with some delay, temperature, humidity, mobility, share of the mutated strains, counter measures including Go To Travel Campaign and an Olympic Games. The study period was February, 2020 through April 14, 2023, as of May 7, 2023.

Results: We selected the specification with 90 days lag of waning. In this specification, the second to the fourth vaccination coverage, the first to the third emergency of status, Goto Travel Campaign and Olympic games and the share of other minor mutated strains were significantly negative. Conversely, share of the alpha, delta, and BA2, BA5, and XBB.1.5 sublineage of omicron variant strain,

The estimated coefficient of after the stopped date for recommendation to wear mask was negative but insignificant.

Discussion: The obtained estimated results showed that mask may not have effectiveness to reduce infection of COVID-19. However, it might suggest that the most of Japanese have continued to wear mask without the government did not recommend after the stopped date.

利益相反に関する開示

No author has any conflict of interest, financial or otherwise, to declare in relation to this study.

ダウンロード *前日までの集計結果を表示します

ダウンロード実績データは、公開の翌日以降に作成されます。

引用文献

European Centre for Disease Prevention and Control. Epidemiological update: SARS-CoV-2 Omicron sub-lineages BA.4 and BA.5. https://www.ecdc.europa.eu/en/news-events/epidemiological-update-sars-cov-2-omicron-sub-lineages-ba4-and-ba.5. [accessed on January 22, 2023]

National Institute of Infectious Diseases. Updated Situation of COVID-19 Outbreak (July 13,2022) https://www.niid.go.jp/niid/ja/2019-ncov/11309-covid19-ab90th.html (in Japanese) [accessed on January 20, 2023]

Ministry of Health, Labour and Welfare. Visualizing the data: information on COVID-19 infections. https://covid19.mhlw.go.jp/en/ [accessed on February 17, 2023]Kurita J, Sugawara T, Ohkusa Y. Estimating Event Ban Effects on COVID-19 Outbreak in Japan. Journal of Health Science and Development 2021. 4: https://www.innovationinfo.org/articles/JHSD/JHSD-137.pdf

Tokyo metropolitan Government. Data of COVID-19 monitoring meeting in metropolitan Tokyo. https://www.bousai.metro.tokyo.lg.jp/taisaku/saigai/1013388/index.html (in Japanese) [accessed February 21,2023].

Prime Minister of Japan and His Cabinet. COVID-19 Vaccines. https://japan.kantei.go.jp/ongoingtopics/vaccine.html [accessed on February 17, 2023]

Levin EG, Lustig Y, Cohen C, et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N Engl J Med 2021:NEJMoa2114583.

Chemaitelly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021:NEJMoa2114114.

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603-15.

Chung H, He S, Nasreen S, et al. Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ 2021;374.

Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernan MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-23.

Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet 2021;397:1646-57.

Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, Simmons R, Cottrell S, Roberts R, O'Doherty M, Brown K, Cameron C, Stockton D, McMenamin J, Ramsay M. Effectiveness of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021;373:n1088.

Bjork J, Inghammar M, Moghaddassi M, Rasmussen M, Malmqvist U, Kahn F. Effectiveness of the BNT162b2 vaccine in preventing COVID-19 in the working age population: first results from a cohort study in southern Sweden. Infect Dis (Lond) 2021;1-6.

Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, O'Horo JC, Virk A, Swift MD, Badley AD, Halamka J, Soundararajan V. FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med (N Y) 2021;2:979-92.e8.

Li B, Deng A, Li K, et al. Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. medRxiv 2021.07.07.21260122; doi: https://doi.org/10.1101/2021.07.07.21260122

ダウンロード

公開済


投稿日時: 2023-05-18 05:29:41 UTC

公開日時: 2023-05-19 10:41:39 UTC

バージョン

改版理由

研究分野
一般医学・社会医学・看護学